Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy

Abroad (travel likely)RecruitingPHASE2

Conditions

Urothelial Carcinoma · Biliary Tract Cancer · HER2

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Contact: Study coordinator (Xiujuan Qu) · qu_xiujuan@hotmail.com · +8613604031355

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC) · Non-small Cell Lung Cancer (NSCLC) · Esophageal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Los Angeles, United States · Grand Rapids, United States

A Phase 2 Clinical Study of ABSK061 and ABSK043

HER2-Gastric/Gastroesophageal Junction Cancer · Urothelial Carcinoma · Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Guiyang, China · Guiyang, China

Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract

Urothelial Carcinoma · Cancer

Abroad (travel likely)RecruitingPHASE2

Paris, France · Marseille, France

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States